z-logo
open-access-imgOpen Access
Solid‐phase synthesis and evaluation of libraries of substituted 4,5‐dihydropyridazinones as vasodilator agents
Author(s) -
Gouault Nicolas,
MartinChouly Corinne A. E.,
Lugnier Claire,
Cupif JeanFrançois,
Tonnelier Amaury,
Feger Frédéric,
Lagente Vincent,
David Michèle
Publication year - 2004
Publication title -
journal of pharmacy and pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.745
H-Index - 118
eISSN - 2042-7158
pISSN - 0022-3573
DOI - 10.1211/0022357043905
Subject(s) - phosphodiesterase 3 , milrinone , chemistry , vasodilation , pharmacology , vascular smooth muscle , phosphodiesterase , inotrope , enzyme , medicine , biochemistry , smooth muscle
The solid‐phase parallel preparation of a library of 4,5‐dihydropyridazin‐3( 2H )‐one derivatives substituted at position 6 with piperazinylmethyl or tetrahydroquinolinylmethyl groups and analogues (3) is reported. Polymer‐supported γ‐keto‐δ‐aminoesters prepared from Wang resin reacted with hydrazine or methylhydrazine to afford pyridazinones in good yields after a cyclization cleavage approach. We have evaluated these novel analogues and several compounds of other series ( 1, 2 ) for their vasorelaxant effect. Among the products tested, 3I and 3d proved to be efficacious and potent relaxant agents of the isolated rat aorta. Inhibitors of phosphodiesterase (PDE3), responsible for the breakdown of cyclic AMP in the vascular smooth muscle, are currently developed for cardiac heart failure because of their inotropic effect and coronary vasodilatation. We had expected that the vasodilatation induced by 3l , as efficient as reference PDE3 inhibitors, milrinone or CI‐930, to be due to PDE3 inhibition. However 3I and 3d exhibited a low inhibitory effect against PDE3 isoenzyme activity. These compounds induced a significant vasorelaxation, which could be of therapeutic interest even if their mechanism of action remains to be determined.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here